University of Southampton-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:University of Southampton - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013270
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
University of Southampton (UOS) is an educational institute that offers undergraduate and postgraduate programs. The university offers educational programs across various disciplines including accounting and finance, acoustical engineering, aeronautics and astronautics, anthropology, archaeology, biochemistry, biology, bio-medical sciences, chemistry, civil engineering, computer science and software engineering, among others. UOS provides other services such as venues, catering and hospitality, outreach and volunteering programmes for schools and other groups and specialist services for businesses. The organization carries out its research activities in partnership with other universities; charities and government bodies; and other business and industries. UOS is headquartered in Southampton, the UK.

University of Southampton – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
University of Southampton, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
University of Southampton, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
University of Southampton, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
University of Southampton, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
University of Southampton, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
University of Southampton, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
BioInvent Enters into Research Agreement with University of Southampton 11
BioInvent and CRT Enter into Research Agreement with University of Southampton 12
C4X Discovery Enters Into Agreement With University of Southampton For New Cyclic Peptides 13
Licensing Agreements 14
BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 14
Synairgen Announces Licensing Agreement With University of Southampton 15
University of Southampton – Key Competitors 16
University of Southampton – Key Employees 17
University of Southampton – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Strategy And Business Planning 19
Oct 07, 2016: UK’s first dedicated Centre for Cancer Immunology reaches development milestone 19
Government and Public Interest 20
Nov 16, 2017: New talking therapy could help cancer survivors cope after treatment 20
Aug 22, 2017: Studies highlight ‘potential new targets for immunotherapy’ 21
Aug 03, 2017: Scientists deliver knock-out blow to multiple cancers 22
Aug 01, 2017: Doctors develop pioneering nose drop to help fight meningitis 23
Jul 13, 2017: Scientists make breakthrough in reversing treatment resistance in blood cancer patients 25
Nov 24, 2016: Human cells with a ‘built-in circuit’ help prevent tumour growth 27
Nov 18, 2016: Pioneering Southampton researchers receive £9m funding boost 28
Sep 23, 2016: New hope in fight against aggressive and often hard to treat brain tumour 29
Sep 14, 2016: Researchers receive £15 million to support pioneering work 30
Jul 25, 2016: New study to help people withdraw from inappropriate long-term antidepressant treatment 32
Jul 22, 2016: University of Southampton: Controlling ADAM33 gene could stop asthma 33
Jul 21, 2016: Stop the rogue ADAM gene and you stop asthma 34
Jun 09, 2016: New molecules identified that could help in the fight to prevent cystic fibrosis 35
May 17, 2016: Funding boost for dementia research 36
May 13, 2016: Southampton leads international team awarded £4 million for cutting-edge cancer research 37
Mar 10, 2016: New study to assess why ‘rogue gene’ causes asthma in early life 38
Mar 02, 2016: Pregnancy vitamin D supplementation may help winter baby’s bones 39
Feb 16, 2016: Southampton genetics and genomics research boosted by new funding 40
Jan 15, 2016: Bone marrow lesions can help predict rapidly progressing joint disease 41
Jan 08, 2016: Study shows beneficial effects of blocking brain inflammation in an experimental model of Alzheimer’s 42
Jan 07, 2016: Study shows beneficial effects of blocking brain inflammation in experimental model of Alzheimer’s 43
Product News 44
Dec 15, 2016: Researchers study potential vaccine to prevent head and neck cancer 44
Aug 11, 2017: Experimental drug trial seeks to improve treatment for lymphoma 46
Feb 07, 2017: Researchers use tiny 3-D spheres to combat tuberculosis 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
University of Southampton, Pharmaceuticals & Healthcare, Key Facts 2
University of Southampton, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
University of Southampton, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
University of Southampton, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
University of Southampton, Deals By Therapy Area, 2011 to YTD 2017 9
University of Southampton, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
BioInvent Enters into Research Agreement with University of Southampton 11
BioInvent and CRT Enter into Research Agreement with University of Southampton 12
C4X Discovery Enters Into Agreement With University of Southampton For New Cyclic Peptides 13
BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 14
Synairgen Announces Licensing Agreement With University of Southampton 15
University of Southampton, Key Competitors 16
University of Southampton, Key Employees 17
University of Southampton, Subsidiaries 18

★海外企業調査レポート[University of Southampton-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Monster Worldwide Inc:企業の戦略的SWOT分析
    Monster Worldwide Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • eLong, Inc.:企業の戦略・SWOT・財務情報
    eLong, Inc. - Strategy, SWOT and Corporate Finance Report Summary eLong, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Komeri Co Ltd:企業の戦略・SWOT・財務情報
    Komeri Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Komeri Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Grupo Mexico SAB de CV:戦略・SWOT・企業財務分析
    Grupo Mexico SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Grupo Mexico SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Efore Oyj (EFO1V):企業の財務・戦略的SWOT分析
    Efore Oyj (EFO1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Batory Foods, Inc.:企業の戦略・SWOT・財務情報
    Batory Foods, Inc. - Strategy, SWOT and Corporate Finance Report Summary Batory Foods, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Martin Midstream Partners L.P.:企業の戦略・SWOT・財務情報
    Martin Midstream Partners L.P. - Strategy, SWOT and Corporate Finance Report Summary Martin Midstream Partners L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Yihai International Holding Ltd (1579):企業の財務・戦略的SWOT分析
    Yihai International Holding Ltd (1579) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Mizuho Trust & Banking Co Ltd:企業の戦略・SWOT・財務情報
    Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Metro Pacific Investments Corporation:企業のM&A・事業提携・投資動向
    Metro Pacific Investments Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Metro Pacific Investments Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed report …
  • Acorda Therapeutics Inc (ACOR):企業の財務・戦略的SWOT分析
    Acorda Therapeutics Inc (ACOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Companhia de Transmissao de Energia Eletrica Paulista (TRPL4):企業の財務・戦略的SWOT分析
    Summary Companhia de Transmissao de Energia Eletrica Paulista (CTEEP) a subsidiary of Interconexion Electrica SA ESP, is an electric utility service provider that produces and distributes electricity. The utility owns and operates power generation plants and transmission lines and supplies electrici …
  • Midea Group Co Ltd:戦略・SWOT・企業財務分析
    Midea Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Midea Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Tyme Technologies Inc (TYME):製薬・医療:M&Aディール及び事業提携情報
    Summary Tyme Technologies Inc (Tyme) is a clinical-stage pharmaceutical company. The company focused on discovering and developing targeted cancer therapeutics for oncology indications. It develops clinical program SM-88, an oral tyrosine-based therapy that is currently in Phase II development for p …
  • Next Fifteen Communications Group plc:企業のM&A・事業提携・投資動向
    Next Fifteen Communications Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Next Fifteen Communications Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed report …
  • French National Institute of Health and Medical Research:医療機器:M&Aディール及び事業提携情報
    Summary French National Institute of Health and Medical Research (INSERM) is a biomedical research institute that conducts research in biology, medicine and public health. The institute offers research in the therapeutic areas of neurosciences, cognitive sciences, neurology, psychiatry, cancer, immu …
  • Natco Pharma Ltd (NATCOPHARM):製薬・医療:M&Aディール及び事業提携情報
    Summary Natco Pharma Ltd (Natco Pharma) focuses on the research, development, manufacture and commercialization of pharmaceutical substances and finished dosage forms. The company offers finished dosage forms in capsule, injection and tablet. Its products are indicated to treat multiple sclerosis, i …
  • Immunovia AB (IMMNOV):企業の財務・戦略的SWOT分析
    Summary Immunovia AB (Immunovia) is a molecular diagnostics company that offers clinical testing for early diagnosis of pancreatic cancer. The company develops IMMray, a technology platform based on antibody microarray analysis, which can be used in the early diagnosis of cancer, predicting disease …
  • Arthrex Inc-医療機器分野:企業M&A・提携分析
    Summary Arthrex Inc (Arthrex), formerly, Arthroscopy Excision Instruments Inc., is a medical device company which designs, and manufactures surgical products and solutions used for arthroscopic and minimally invasive orthopedic surgical procedures. The company offers shoulder, knee, elbow, hand and …
  • Adtran Inc (ADTN):企業の財務・戦略的SWOT分析
    Adtran Inc (ADTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆